Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ARG1 | P05089 | 1/20 | 0.39 |
| ▸ | ARG2 | P78540 | 1/20 | 0.39 |
| ▸ | HTR2A | P28223 | 7/20 | 0.37 |
| ▸ | HRH1 | P35367 | 5/20 | 0.37 |
| ▸ | HTR2C | P28335 | 13/20 | 0.36 |
| ▸ | DRD2 | P14416 | 5/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | HTR2B | P41595 | 4/20 | 0.33 |
| ▸ | DRD1 | P21728 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL499877 | 0.81 | HTR2A (0.40) | HTR2AHRH1HTR2CDRD2GAA | |
| Hydrochloric Acid SCHEMBL48286 | 0.79 | HRH1 (0.39) | HTR2AHRH1HTR2CDRD2HTR2B | |
| SCHEMBL3696273 | 0.79 | SMN1; SMN2 (0.41) | ARG1ARG2HTR2AHRH1HTR2C | |
| SCHEMBL3690635 | 0.78 | HTR2A (0.44) | HTR2AHRH1HTR2CDRD2HTR2B | |
| SCHEMBL22557833 | 0.76 | SIGMAR1 (0.45) | HTR2AHRH1HTR2CDRD2ALDH1A1 | |
| SCHEMBL7361325 | 0.76 | HSD17B10 (0.48) | GAAALDH1A1 | |
| SCHEMBL26962168 | 0.74 | RAB9A (0.38) | HTR2AHRH1HTR2CDRD2HTR2B | |
| SCHEMBL22556962 | 0.74 | HTR2C (0.43) | ARG1ARG2HTR2AHRH1HTR2C | |
| SCHEMBL3690441 | 0.74 | HTR2A (0.39) | HTR2AHRH1HTR2CDRD2HTR2B | |
| SCHEMBL4762520 | 0.73 | GAA (0.41) | GAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | MATIER WILLIAM L (US) | 2013-05-23 | — | — | US | disclosed |
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | MATIER WILLIAM L (US) | 2013-05-23 | — | — | US | disclosed |
| US-8383648-B2 | Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery | COLBY PHARMACEUTICAL COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383648-B2 | Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery | COLBY PHARMACEUTICAL COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383648-B2 | Applying such as 1-oxyl-4-(3'-ethoxy-2',2'-dimethyl)propanecarbonyloxy-2,2,6,6-tetramethylpiperidine to eye surface; halting growth, preventing surgery | COLBY PHARMACEUTICAL COMPANY (US) | 2013-02-26 | — | — | US | disclosed |
| US-7825134-B2 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825134-B2 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-7825134-B2 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2010-11-02 | — | — | US | disclosed |
| US-20080274983-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | OTHERA HOLDING, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080274983-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | OTHERA HOLDING, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-20080274983-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | OTHERA HOLDING, INC. (US) | 2008-11-06 | — | — | US | disclosed |
| US-7442711-B2 | Amelioration of the development of cataracts and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442711-B2 | Amelioration of the development of cataracts and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-7442711-B2 | Amelioration of the development of cataracts and other ophthalmic diseases | OTHERA HOLDING, INC. (US) | 2008-10-28 | — | — | US | disclosed |
| US-20050131025-A1 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | COLBY PHARMACEUTICAL COMPANY | 2005-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080274983-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | C3AR1, C1R, AKR1C3 | ARG1 92/4885ARG2 128/4885HTR2A 3323/4885 |
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | C3AR1, C1R, AKR1C3 | ARG1 92/4885ARG2 128/4885HTR2A 3323/4885 |
| US-20050131025-A1 | Amelioration of cataracts, macular degeneration and other ophthalmic diseases | C1R, CRYAB, C9 | ARG1 159/4885ARG2 222/4885HTR2A 3810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.